We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Mr Lee’s Pure Foods is an innovative food/tech company creating award-winning premium healthy noodles-in-a-cup and will be launching its new instant Congee Asian rice porridge. All products are certified low sugar, gluten-free, low on calories, Vegan options and 100% recyclable and compostable packaging. The global instant noodle market is expected to reach $57.5 billion by 2024 which the brand aims to capitalise on and establish itself in as the market leader. Mr Lee's has won 50+ global awards and nominations including Grocer Gold Exporter of the Year, Great British Entrepreneur winner, and The Sunday Times Maserati 100 winner. Noted publisher Penguin Random House has published Mr Lee’s 100 Noodle Recipe cookbook which has been met with critical acclaim worldwide. With the investment, the company will invest 25% of it in marketing initiatives and entering into the US market, 10% in product development, 20% in working capital for food production during scale-up, 5% in upgrading its Hot Noodle Kiosk and vending machine facilities, and 40% in global group operating and personnel costs runway for commercial functions and scale-up activities within Australia, the UK, and the USA.

Pitch Rated

56%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,835,892
Mr Lee's Noodles are an award winning, healthy, tasty and convenient noodles in a cup. They are low in salt, with no sat fats and are gluten free. They also have created an interactive noodle kiosk which delivers a hot noodle meal 24/7 and are looking to partner with catering and retail giants.   
days to go: Expired investment: £843,560
Native Products are a modern grooming brand developed by barbers and they now have a range of 7 men's grooming products with a further 8 in the pipeline. They are stocked across the UK, Europe, Asia and America, with plans to launch new products and grow their sales through stockists and online. 
days to go: Expired investment: £32,400
EarlyBird have created a number of different healthy snack packs, all made with fresh ingredients. EarlyBird deliver their snacks straight to your door meaning you don't have to leave the comfort of your home. 
days to go: Expired investment: £168,000
Saint Aymes' handmade chocolate launched in December 2016 following a masterclass with Sir Richard Branson and are sold among independent boutiques internationally aswell as Selfridges, Fenwick and Harvey Nichols. They aim to bring superior brand experience to the £6.6bn UK confectionery market.
days to go: Expired investment: £13,280
'Revolution Race Cars' is the brainchild of a team of British designers, engineers, and industry specialists. The company has produced an all-new race car: Revolution A-One that challenges not only the status quo but also changes the postcode. The car is created after eighteen months of R&D, rigorous selection, and 4,000 miles of extreme testing of Revolution's suppliers and partners. The official production of Revolution A-One started in May 2019, and its sales have already been recorded in three countries. With the proceeds, the company will optimise its production cycle for future expansion.
days to go: Expired investment: £392,220
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph